PROMID
Showed for the first time that a hormone-suppressing injection also slows neuroendocrine tumour growth.
Time to tumour progression 14.3 vs 6.0 months (HR 0.34); no OS difference (crossover, low event rate).
Setting
Treatment-naive metastatic midgut NETs: octreotide LAR vs placebo
Phase
Phase 3
Sponsor
Novartis / German NET study group
Registry
Headline result
TTP 14.3 vs 6.0 months, HR 0.34.
Reported
2009
Enrolled
85
Replication
CLARINET extended the antiproliferative effect to lanreotide across enteropancreatic NETs.
In plain words
What these results mean for people, not percentages
Time to tumour progressionprimaryother endpoint
- Median 14.3 vs 6 months with Octreotide LAR compared with Placebo; about 8.3 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 66 percent lower chance of the event at any given time (hazard ratio 0.34, likely range 0.2 to 0.59).
- This endpoint is not one of the standard survival or response measures; read it alongside the trial's primary result.
- These results apply to the people the trial enrolled: Treatment-naive metastatic midgut NETs: octreotide LAR vs placebo. People in a different situation may not see the same effect.
- Only 85 people took part, so the numbers are less certain than in a large trial.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
85 participants enrolled.
Time to tumour progressionprimary
HR 0.34 (0.2–0.59)
Octreotide LAR
14.3 mo
Placebo
6 mo
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Time to tumour progressionprimary | Octreotide LAR | 42 | 14.3 months | 0.34 (0.2–0.59) | — | — |
| Placebo | 43 | 6 months |
Replication
CLARINET extended the antiproliferative effect to lanreotide across enteropancreatic NETs.Pages like this
not linked directly; found by shared links- TermCarcinoid syndrome and carcinoid heart disease
Shares Somatostatin analogues (octreotide, lanreotide), Neuroendocrine tumours.
- TrialCLARINET
Shares Somatostatin analogues (octreotide, lanreotide), Neuroendocrine tumours.
- CompanyIpsen
Shares Somatostatin analogues (octreotide, lanreotide), Neuroendocrine tumours.
- TargetSomatostatin receptor 2
Shares Somatostatin analogues (octreotide, lanreotide), Neuroendocrine tumours.